Long Pentraxin 3 as a Predictive Marker of Mortality in Severe Septic Patients Who Received Successful Early Goal-Directed Therapy

Pentraxin 3 (PTX3) has been suggested to be a prognostic marker of mortality in severe sepsis. Currently, there are limited data on biomarkers including PTX3 that can be used to predict mortality in severe sepsis patients who have undergone successful initial resuscitation through early goal-directe...

Full description

Saved in:
Bibliographic Details
Published inYonsei medical journal Vol. 58; no. 2; pp. 370 - 379
Main Authors Kim, Sun Bean, Lee, Kyoung Hwa, Lee, Ji Un, Ann, Hea Won, Ahn, Jin Young, Jeon, Yong Duk, Kim, Jung Ho, Ku, Nam Su, Han, Sang Hoon, Choi, Jun Yong, Song, Young Goo, Kim, June Myung
Format Journal Article
LanguageEnglish
Published Korea (South) Yonsei University College of Medicine 01.03.2017
연세대학교의과대학
Subjects
Online AccessGet full text
ISSN0513-5796
1976-2437
1976-2437
DOI10.3349/ymj.2017.58.2.370

Cover

Abstract Pentraxin 3 (PTX3) has been suggested to be a prognostic marker of mortality in severe sepsis. Currently, there are limited data on biomarkers including PTX3 that can be used to predict mortality in severe sepsis patients who have undergone successful initial resuscitation through early goal-directed therapy (EGDT). A prospective cohort study was conducted among 83 severe sepsis patients with fulfillment of all EGDT components and the achievement of final goal. Plasma PTX3 levels were measured by sandwich ELISA on hospital day (HD) 0, 3, and 7. The data for procalcitonin, C-reactive protein and delta neutrophil index were collected by electric medical record. The primary outcome was 28-day all-cause mortality. 28-day all-cause mortality was 19.3% and the median (interquartile range) APHCH II score of total patients was 16 (13-19). The non-survivors (n=16) had significantly higher PTX3 level at HD 0 [201.4 (56.9-268.6) ng/mL vs. 36.5 (13.7-145.3) ng/mL, p=0.008]. PTX3 had largest AUC(ROC) value for the prediction of mortality among PTX3, procalcitonin, delta neutrophil index, CRP and APACHE II/SOFA sore at HD 0 [0.819, 95% confidence interval (CI) 0.677-0.961, p=0.008]. The most valid cut-off level of PTX3 at HD 0 was 140.28 ng/mL (sensitivity 66.7%, specificity 73.8%). The PTX3 and procalcitonin at HD 0 showed strong correlation (r=0.675, p<0.001). However, PTX3 at HD 0 was the only independent predictive marker in Cox's proportional hazards model (≥140 ng/mL; hazard rate 7.16, 95% CI 2.46-15.85, p=0.001). PTX3 at HD 0 could be a powerful predictive biomarker of 28-day all-cause mortality in severe septic patients who have undergone successful EGDT.
AbstractList Pentraxin 3 (PTX3) has been suggested to be a prognostic marker of mortality in severe sepsis. Currently, there are limited data on biomarkers including PTX3 that can be used to predict mortality in severe sepsis patients who have undergone successful initial resuscitation through early goal-directed therapy (EGDT).PURPOSEPentraxin 3 (PTX3) has been suggested to be a prognostic marker of mortality in severe sepsis. Currently, there are limited data on biomarkers including PTX3 that can be used to predict mortality in severe sepsis patients who have undergone successful initial resuscitation through early goal-directed therapy (EGDT).A prospective cohort study was conducted among 83 severe sepsis patients with fulfillment of all EGDT components and the achievement of final goal. Plasma PTX3 levels were measured by sandwich ELISA on hospital day (HD) 0, 3, and 7. The data for procalcitonin, C-reactive protein and delta neutrophil index were collected by electric medical record. The primary outcome was 28-day all-cause mortality.MATERIALS AND METHODSA prospective cohort study was conducted among 83 severe sepsis patients with fulfillment of all EGDT components and the achievement of final goal. Plasma PTX3 levels were measured by sandwich ELISA on hospital day (HD) 0, 3, and 7. The data for procalcitonin, C-reactive protein and delta neutrophil index were collected by electric medical record. The primary outcome was 28-day all-cause mortality.28-day all-cause mortality was 19.3% and the median (interquartile range) APHCH II score of total patients was 16 (13-19). The non-survivors (n=16) had significantly higher PTX3 level at HD 0 [201.4 (56.9-268.6) ng/mL vs. 36.5 (13.7-145.3) ng/mL, p=0.008]. PTX3 had largest AUC(ROC) value for the prediction of mortality among PTX3, procalcitonin, delta neutrophil index, CRP and APACHE II/SOFA sore at HD 0 [0.819, 95% confidence interval (CI) 0.677-0.961, p=0.008]. The most valid cut-off level of PTX3 at HD 0 was 140.28 ng/mL (sensitivity 66.7%, specificity 73.8%). The PTX3 and procalcitonin at HD 0 showed strong correlation (r=0.675, p<0.001). However, PTX3 at HD 0 was the only independent predictive marker in Cox's proportional hazards model (≥140 ng/mL; hazard rate 7.16, 95% CI 2.46-15.85, p=0.001).RESULTS28-day all-cause mortality was 19.3% and the median (interquartile range) APHCH II score of total patients was 16 (13-19). The non-survivors (n=16) had significantly higher PTX3 level at HD 0 [201.4 (56.9-268.6) ng/mL vs. 36.5 (13.7-145.3) ng/mL, p=0.008]. PTX3 had largest AUC(ROC) value for the prediction of mortality among PTX3, procalcitonin, delta neutrophil index, CRP and APACHE II/SOFA sore at HD 0 [0.819, 95% confidence interval (CI) 0.677-0.961, p=0.008]. The most valid cut-off level of PTX3 at HD 0 was 140.28 ng/mL (sensitivity 66.7%, specificity 73.8%). The PTX3 and procalcitonin at HD 0 showed strong correlation (r=0.675, p<0.001). However, PTX3 at HD 0 was the only independent predictive marker in Cox's proportional hazards model (≥140 ng/mL; hazard rate 7.16, 95% CI 2.46-15.85, p=0.001).PTX3 at HD 0 could be a powerful predictive biomarker of 28-day all-cause mortality in severe septic patients who have undergone successful EGDT.CONCLUSIONPTX3 at HD 0 could be a powerful predictive biomarker of 28-day all-cause mortality in severe septic patients who have undergone successful EGDT.
Purpose: Pentraxin 3 (PTX3) has been suggested to be a prognostic marker of mortality in severe sepsis. Currently, there are limiteddata on biomarkers including PTX3 that can be used to predict mortality in severe sepsis patients who have undergone successfulinitial resuscitation through early goal-directed therapy (EGDT). Materials and Methods: A prospective cohort study was conducted among 83 severe sepsis patients with fulfillment of all EGDT components and the achievement of final goal. Plasma PTX3 levels were measured by sandwich ELISA on hospital day (HD) 0, 3, and 7. The data for procalcitonin, C-reactive protein and delta neutrophil index were collected by electric medical record. The primary outcome was 28-day all-cause mortality. Results: 28-day all-cause mortality was 19.3% and the median (interquartile range) APHCH II score of total patients was 16 (13–19). The non-survivors (n=16) had significantly higher PTX3 level at HD 0 [201.4 (56.9–268.6) ng/mL vs. 36.5 (13.7–145.3) ng/mL, p=0.008]. PTX3 had largest AUCROC value for the prediction of mortality among PTX3, procalcitonin, delta neutrophil index, CRP and APACHE II/SOFA sore at HD 0 [0.819, 95% confidence interval (CI) 0.677–0.961, p=0.008]. The most valid cut-off level of PTX3 at HD 0 was 140.28 ng/mL (sensitivity 66.7%, specificity 73.8%). The PTX3 and procalcitonin at HD 0 showed strong correlation (r=0.675, p<0.001). However, PTX3 at HD 0 was the only independent predictive marker in Cox’s proportional hazards model (≥140 ng/mL; hazard rate 7.16, 95% CI 2.46–15.85, p=0.001). Conclusion: PTX3 at HD 0 could be a powerful predictive biomarker of 28-day all-cause mortality in severe septic patients who have undergone successful EGDT KCI Citation Count: 8
Pentraxin 3 (PTX3) has been suggested to be a prognostic marker of mortality in severe sepsis. Currently, there are limited data on biomarkers including PTX3 that can be used to predict mortality in severe sepsis patients who have undergone successful initial resuscitation through early goal-directed therapy (EGDT). A prospective cohort study was conducted among 83 severe sepsis patients with fulfillment of all EGDT components and the achievement of final goal. Plasma PTX3 levels were measured by sandwich ELISA on hospital day (HD) 0, 3, and 7. The data for procalcitonin, C-reactive protein and delta neutrophil index were collected by electric medical record. The primary outcome was 28-day all-cause mortality. 28-day all-cause mortality was 19.3% and the median (interquartile range) APHCH II score of total patients was 16 (13-19). The non-survivors (n=16) had significantly higher PTX3 level at HD 0 [201.4 (56.9-268.6) ng/mL vs. 36.5 (13.7-145.3) ng/mL, p=0.008]. PTX3 had largest AUC(ROC) value for the prediction of mortality among PTX3, procalcitonin, delta neutrophil index, CRP and APACHE II/SOFA sore at HD 0 [0.819, 95% confidence interval (CI) 0.677-0.961, p=0.008]. The most valid cut-off level of PTX3 at HD 0 was 140.28 ng/mL (sensitivity 66.7%, specificity 73.8%). The PTX3 and procalcitonin at HD 0 showed strong correlation (r=0.675, p<0.001). However, PTX3 at HD 0 was the only independent predictive marker in Cox's proportional hazards model (≥140 ng/mL; hazard rate 7.16, 95% CI 2.46-15.85, p=0.001). PTX3 at HD 0 could be a powerful predictive biomarker of 28-day all-cause mortality in severe septic patients who have undergone successful EGDT.
Author Song, Young Goo
Lee, Kyoung Hwa
Jeon, Yong Duk
Han, Sang Hoon
Choi, Jun Yong
Kim, June Myung
Kim, Sun Bean
Kim, Jung Ho
Ann, Hea Won
Lee, Ji Un
Ku, Nam Su
Ahn, Jin Young
AuthorAffiliation 1 Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
2 Department of Internal Medicine, Infectious Diseases, Hongik Hospital, Seoul, Korea
AuthorAffiliation_xml – name: 2 Department of Internal Medicine, Infectious Diseases, Hongik Hospital, Seoul, Korea
– name: 1 Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
Author_xml – sequence: 1
  givenname: Sun Bean
  surname: Kim
  fullname: Kim, Sun Bean
  organization: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
– sequence: 2
  givenname: Kyoung Hwa
  surname: Lee
  fullname: Lee, Kyoung Hwa
  organization: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
– sequence: 3
  givenname: Ji Un
  surname: Lee
  fullname: Lee, Ji Un
  organization: Department of Internal Medicine, Infectious Diseases, Hongik Hospital, Seoul, Korea
– sequence: 4
  givenname: Hea Won
  surname: Ann
  fullname: Ann, Hea Won
  organization: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
– sequence: 5
  givenname: Jin Young
  surname: Ahn
  fullname: Ahn, Jin Young
  organization: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
– sequence: 6
  givenname: Yong Duk
  surname: Jeon
  fullname: Jeon, Yong Duk
  organization: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
– sequence: 7
  givenname: Jung Ho
  surname: Kim
  fullname: Kim, Jung Ho
  organization: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
– sequence: 8
  givenname: Nam Su
  surname: Ku
  fullname: Ku, Nam Su
  organization: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
– sequence: 9
  givenname: Sang Hoon
  surname: Han
  fullname: Han, Sang Hoon
  organization: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
– sequence: 10
  givenname: Jun Yong
  surname: Choi
  fullname: Choi, Jun Yong
  organization: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
– sequence: 11
  givenname: Young Goo
  surname: Song
  fullname: Song, Young Goo
  organization: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
– sequence: 12
  givenname: June Myung
  surname: Kim
  fullname: Kim, June Myung
  organization: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28120568$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002196523$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNp9kk9vEzEQxS1URNPCB-CCfITDLv6z9novSFVpS6VURG0QR8vxjhs3m3WwNxG59pPjJKUCDkiW5jC_92bkeSfoqA89IPSWkpLzqvm4XT6UjNC6FKpkJa_JCzSiTS0LVvH6CI2IoLwQdSOP0UlKD4SwmhL2Ch0zRRkRUo3Q4zj093gC_RDNT99jjk3CBk8itN4OfgP4xsQFRBwcvglxMJ0ftjiDd7CBCLmsBm_xxAw-eyT8fR7wLVjIyhbfra2FlNy6wxcmdlt8FUxXfPYR7JDb0zlEs9q-Ri-d6RK8eaqn6NvlxfT8SzH-enV9fjYubMX5UFSy4sCYaoTj0EjFZrSyvOFOciFIY5RoedsI6RQFJp1zppmBsjNTE9VKRvkp-nDw7aPTC-t1MH5f74NeRH12O73WlDPFlczspwO7Ws-W0Nr9_3R6Ff3SxO1e-Xen9_Pss9GCNSRfJBu8fzKI4cca0qCXPlnoOtNDWCdNldw_KjL67s9Zz0N-HykD9ADYGFKK4J4RSvQuCDoHQe-CoIXSTOcgZE39j8b6IR8p7Nb13X-UvwBFobmD
CitedBy_id crossref_primary_10_1016_j_jinf_2020_01_010
crossref_primary_10_1186_s12879_019_4618_7
crossref_primary_10_1186_s13054_022_04032_x
crossref_primary_10_1016_j_jcrc_2018_06_004
crossref_primary_10_18632_oncotarget_23701
crossref_primary_10_3947_ic_2020_52_1_1
crossref_primary_10_4103_njcp_njcp_615_23
crossref_primary_10_3389_fimmu_2019_00794
crossref_primary_10_1016_j_jinf_2017_10_016
crossref_primary_10_3390_biomedicines9030311
crossref_primary_10_3389_fimmu_2019_00823
crossref_primary_10_1016_j_jinf_2018_04_014
crossref_primary_10_3389_fmed_2024_1398024
crossref_primary_10_1371_journal_pone_0243849
crossref_primary_10_1080_17460441_2021_1851186
Cites_doi 10.1097/01.CCM.0000298158.12101.41
10.1086/377200
10.1016/j.hrtlng.2012.11.005
10.3349/ymj.2016.57.1.111
10.1016/j.jinf.2011.08.004
10.1007/s00134-003-1662-x
10.1182/blood.V87.5.1862.1862
10.1111/j.1440-1843.2011.02018.x
10.1001/jama.2009.1754
10.1056/NEJMoa1211161
10.1016/j.jinf.2009.04.004
10.1097/00003246-200107000-00017
10.1371/journal.pone.0073119
10.1155/2013/165974
10.1186/cc13145
10.3324/haematol.2011.044925
10.1097/CCM.0b013e3181809aaf
10.1097/01.CCM.0000117317.18092.E4
10.1371/journal.pone.0017653
10.1586/eri.13.9
10.1016/0021-9681(87)90171-8
10.1007/BF01709751
10.1002/hep.25551
10.1186/1471-2334-11-299
10.1159/000339789
10.1097/00003246-198510000-00009
10.1111/j.1600-065X.2008.00719.x
10.1155/2012/920517
10.1007/s00134-012-2769-8
10.1371/journal.pone.0053661
10.1080/00365519709168308
10.1378/chest.115.3.829
10.1097/SHK.0b013e31817fd543
10.1097/SHK.0b013e3182454acf
10.1056/NEJMoa010307
10.1016/j.ajem.2012.10.017
10.1515/cclm-2012-0459
10.1016/S0021-9258(18)41653-5
10.1007/s00134-010-1752-5
ContentType Journal Article
Copyright Copyright: Yonsei University College of Medicine 2017 2017
Copyright_xml – notice: Copyright: Yonsei University College of Medicine 2017 2017
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ACYCR
DOI 10.3349/ymj.2017.58.2.370
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Korean Citation Index
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1976-2437
EndPage 379
ExternalDocumentID oai_kci_go_kr_ARTI_1328386
PMC5290017
28120568
10_3349_ymj_2017_58_2_370
Genre Journal Article
GroupedDBID ---
.55
.GJ
123
29R
2WC
36B
5-W
53G
5RE
8JR
8XY
9ZL
AAYXX
ACYCR
ADBBV
ADRAZ
AEGXH
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
CS3
DIK
DU5
E3Z
EBD
EF.
EMB
EMOBN
F5P
GROUPED_DOAJ
GX1
HYE
KQ8
L7B
M48
MK0
O5R
O5S
OK1
OVT
P2P
PGMZT
RNS
RPM
SV3
TR2
X7M
XSB
ZGI
ZXP
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
M~E
ID FETCH-LOGICAL-c433t-4643e22895f3e9682b14c393f635509a85d3d956f81e26fffa9be8cba708d6213
IEDL.DBID M48
ISSN 0513-5796
1976-2437
IngestDate Tue Nov 21 21:40:30 EST 2023
Thu Aug 21 18:31:11 EDT 2025
Thu Jul 10 18:18:55 EDT 2025
Thu Apr 03 07:02:00 EDT 2025
Thu Apr 24 23:06:44 EDT 2025
Tue Jul 01 04:03:06 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords mortality
predictive biomarker
Pentraxin 3
severe sepsis
early-goal directed therapy
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c433t-4643e22895f3e9682b14c393f635509a85d3d956f81e26fffa9be8cba708d6213
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
G704-000409.2017.58.2.012
http://ymj.kr/DOIx.php?id=10.3349/ymj.2017.58.2.370
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3349/ymj.2017.58.2.370
PMID 28120568
PQID 1861861815
PQPubID 23479
PageCount 10
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_1328386
pubmedcentral_primary_oai_pubmedcentral_nih_gov_5290017
proquest_miscellaneous_1861861815
pubmed_primary_28120568
crossref_primary_10_3349_ymj_2017_58_2_370
crossref_citationtrail_10_3349_ymj_2017_58_2_370
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2017-03-01
PublicationDateYYYYMMDD 2017-03-01
PublicationDate_xml – month: 03
  year: 2017
  text: 2017-03-01
  day: 01
PublicationDecade 2010
PublicationPlace Korea (South)
PublicationPlace_xml – name: Korea (South)
PublicationTitle Yonsei medical journal
PublicationTitleAlternate Yonsei Med J
PublicationYear 2017
Publisher Yonsei University College of Medicine
연세대학교의과대학
Publisher_xml – name: Yonsei University College of Medicine
– name: 연세대학교의과대학
References Park (10.3349/ymj.2017.58.2.370_ref37) 2011; 11
Rivers (10.3349/ymj.2017.58.2.370_ref17) 2001; 345
Charlson (10.3349/ymj.2017.58.2.370_ref18) 1987; 40
Kang (10.3349/ymj.2017.58.2.370_ref21) 2003; 37
Cunha (10.3349/ymj.2017.58.2.370_ref40) 2014; 370
Vincent (10.3349/ymj.2017.58.2.370_ref35) 2013; 11
Vänskä (10.3349/ymj.2017.58.2.370_ref28) 2011; 96
Vincent (10.3349/ymj.2017.58.2.370_ref19) 1996; 22
Huttunen (10.3349/ymj.2017.58.2.370_ref31) 2011; 6
Breviario (10.3349/ymj.2017.58.2.370_ref3) 1992; 267
Kunes (10.3349/ymj.2017.58.2.370_ref14) 2012; 2012
Nahm (10.3349/ymj.2017.58.2.370_ref24) 2008; 38
Knaus (10.3349/ymj.2017.58.2.370_ref20) 1985; 13
Dellinger (10.3349/ymj.2017.58.2.370_ref26) 2004; 32
Kao (10.3349/ymj.2017.58.2.370_ref34) 2013; 51
Hasday (10.3349/ymj.2017.58.2.370_ref2) 1999; 115
Vincent (10.3349/ymj.2017.58.2.370_ref5) 2009; 302
Lee (10.3349/ymj.2017.58.2.370_ref7) 2016; 57
Boyd (10.3349/ymj.2017.58.2.370_ref27) 1997; 227
Mauri (10.3349/ymj.2017.58.2.370_ref10) 2008; 36
Lee (10.3349/ymj.2017.58.2.370_ref23) 2012; 55
Muller (10.3349/ymj.2017.58.2.370_ref11) 2001; 29
Dellinger (10.3349/ymj.2017.58.2.370_ref6) 2013; 39
Huttunen (10.3349/ymj.2017.58.2.370_ref9) 2011; 63
Mauri (10.3349/ymj.2017.58.2.370_ref29) 2010; 36
Uusitalo-Seppälä (10.3349/ymj.2017.58.2.370_ref12) 2013; 8
Huh (10.3349/ymj.2017.58.2.370_ref25) 2011; 16
Khwaja (10.3349/ymj.2017.58.2.370_ref22) 2012; 120
Seok (10.3349/ymj.2017.58.2.370_ref36) 2012; 37
Sprong (10.3349/ymj.2017.58.2.370_ref33) 2009; 31
Bottazzi (10.3349/ymj.2017.58.2.370_ref1) 2009; 227
Introna (10.3349/ymj.2017.58.2.370_ref4) 1996; 87
Lin (10.3349/ymj.2017.58.2.370_ref30) 2013; 42
Dellinger (10.3349/ymj.2017.58.2.370_ref15) 2008; 36
Levy (10.3349/ymj.2017.58.2.370_ref16) 2003; 29
Schulte (10.3349/ymj.2017.58.2.370_ref8) 2013; 2013
Wagenaar (10.3349/ymj.2017.58.2.370_ref32) 2009; 58
Bastrup-Birk (10.3349/ymj.2017.58.2.370_ref13) 2013; 8
Kim (10.3349/ymj.2017.58.2.370_ref38) 2013; 17
Jo (10.3349/ymj.2017.58.2.370_ref39) 2013; 31
26632390 - Yonsei Med J. 2016 Jan;57(1):111-7
12664219 - Intensive Care Med. 2003 Apr;29(4):530-8
20119647 - Intensive Care Med. 2010 Apr;36(4):621-9
19443038 - J Infect. 2009 Jun;58(6):425-32
11794169 - N Engl J Med. 2001 Nov 8;345(19):1368-77
8844239 - Intensive Care Med. 1996 Jul;22(7):707-10
19952319 - JAMA. 2009 Dec 2;302(21):2323-9
22258230 - Shock. 2012 Mar;37(3):242-6
23380094 - Am J Emerg Med. 2013 Mar;31(3):545-8
9127468 - Scand J Clin Lab Invest Suppl. 1997;227:46-63
3928249 - Crit Care Med. 1985 Oct;13(10):818-29
18158437 - Crit Care Med. 2008 Jan;36(1):296-327
18596636 - Crit Care Med. 2008 Aug;36(8):2302-8
12955633 - Clin Infect Dis. 2003 Sep 15;37(6):745-51
22890468 - Nephron Clin Pract. 2012;120(4):c179-84
1429570 - J Biol Chem. 1992 Nov 5;267(31):22190-7
23458767 - Expert Rev Anti Infect Ther. 2013 Mar;11(3):265-75
24039869 - PLoS One. 2013 Sep 09;8(9):e73119
23341967 - PLoS One. 2013;8(1):e53661
23361625 - Intensive Care Med. 2013 Feb;39(2):165-228
24321201 - Crit Care. 2013 Dec 09;17(6):R282
22577258 - Mediators Inflamm. 2012;2012:920517
11445697 - Crit Care Med. 2001 Jul;29(7):1404-7
15090974 - Crit Care Med. 2004 Mar;32(3):858-73
23273657 - Heart Lung. 2013 Mar-Apr;42(2):139-45
21423699 - PLoS One. 2011 Mar 10;6(3):e17653
3558716 - J Chronic Dis. 1987;40(5):373-83
21840338 - J Infect. 2011 Dec;63(6):407-19
21880642 - Haematologica. 2011 Sep;96(9):1385-9
10084499 - Chest. 1999 Mar;115(3):829-35
18715852 - Ann Clin Lab Sci. 2008 Summer;38(3):241-6
22040292 - BMC Infect Dis. 2011 Nov 01;11:299
8634434 - Blood. 1996 Mar 1;87(5):1862-72
22213561 - Hepatology. 2012 Mar;55(3):965-7
24476432 - N Engl J Med. 2014 Jan 30;370(5):421-32
18650775 - Shock. 2009 Jan;31(1):28-32
19120471 - Immunol Rev. 2009 Jan;227(1):9-18
21726354 - Respirology. 2011 Oct;16(7):1088-95
23152412 - Clin Chem Lab Med. 2013 Apr;51(4):907-13
23853427 - Mediators Inflamm. 2013;2013:165974
References_xml – volume: 36
  start-page: 296
  year: 2008
  ident: 10.3349/ymj.2017.58.2.370_ref15
  publication-title: Crit Care Med
  doi: 10.1097/01.CCM.0000298158.12101.41
– volume: 37
  start-page: 745
  year: 2003
  ident: 10.3349/ymj.2017.58.2.370_ref21
  publication-title: Clin Infect Dis
  doi: 10.1086/377200
– volume: 42
  start-page: 139
  year: 2013
  ident: 10.3349/ymj.2017.58.2.370_ref30
  publication-title: Heart Lung
  doi: 10.1016/j.hrtlng.2012.11.005
– volume: 57
  start-page: 111
  year: 2016
  ident: 10.3349/ymj.2017.58.2.370_ref7
  publication-title: Yonsei Med J
  doi: 10.3349/ymj.2016.57.1.111
– volume: 63
  start-page: 407
  year: 2011
  ident: 10.3349/ymj.2017.58.2.370_ref9
  publication-title: J Infect
  doi: 10.1016/j.jinf.2011.08.004
– volume: 29
  start-page: 530
  year: 2003
  ident: 10.3349/ymj.2017.58.2.370_ref16
  publication-title: Intensive Care Med
  doi: 10.1007/s00134-003-1662-x
– volume: 87
  start-page: 1862
  year: 1996
  ident: 10.3349/ymj.2017.58.2.370_ref4
  publication-title: Blood
  doi: 10.1182/blood.V87.5.1862.1862
– volume: 16
  start-page: 1088
  year: 2011
  ident: 10.3349/ymj.2017.58.2.370_ref25
  publication-title: Respirology
  doi: 10.1111/j.1440-1843.2011.02018.x
– volume: 302
  start-page: 2323
  year: 2009
  ident: 10.3349/ymj.2017.58.2.370_ref5
  publication-title: JAMA
  doi: 10.1001/jama.2009.1754
– volume: 370
  start-page: 421
  year: 2014
  ident: 10.3349/ymj.2017.58.2.370_ref40
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1211161
– volume: 58
  start-page: 425
  year: 2009
  ident: 10.3349/ymj.2017.58.2.370_ref32
  publication-title: J Infect
  doi: 10.1016/j.jinf.2009.04.004
– volume: 29
  start-page: 1404
  year: 2001
  ident: 10.3349/ymj.2017.58.2.370_ref11
  publication-title: Crit Care Med
  doi: 10.1097/00003246-200107000-00017
– volume: 8
  start-page: e73119
  year: 2013
  ident: 10.3349/ymj.2017.58.2.370_ref13
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0073119
– volume: 2013
  start-page: 165974
  year: 2013
  ident: 10.3349/ymj.2017.58.2.370_ref8
  publication-title: Mediators Inflamm
  doi: 10.1155/2013/165974
– volume: 17
  start-page: R282
  year: 2013
  ident: 10.3349/ymj.2017.58.2.370_ref38
  publication-title: Crit Care
  doi: 10.1186/cc13145
– volume: 96
  start-page: 1385
  year: 2011
  ident: 10.3349/ymj.2017.58.2.370_ref28
  publication-title: Haematologica
  doi: 10.3324/haematol.2011.044925
– volume: 36
  start-page: 2302
  year: 2008
  ident: 10.3349/ymj.2017.58.2.370_ref10
  publication-title: Crit Care Med
  doi: 10.1097/CCM.0b013e3181809aaf
– volume: 32
  start-page: 858
  year: 2004
  ident: 10.3349/ymj.2017.58.2.370_ref26
  publication-title: Crit Care Med
  doi: 10.1097/01.CCM.0000117317.18092.E4
– volume: 6
  start-page: e17653
  year: 2011
  ident: 10.3349/ymj.2017.58.2.370_ref31
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0017653
– volume: 11
  start-page: 265
  year: 2013
  ident: 10.3349/ymj.2017.58.2.370_ref35
  publication-title: Expert Rev Anti Infect Ther
  doi: 10.1586/eri.13.9
– volume: 40
  start-page: 373
  year: 1987
  ident: 10.3349/ymj.2017.58.2.370_ref18
  publication-title: J Chronic Dis
  doi: 10.1016/0021-9681(87)90171-8
– volume: 22
  start-page: 707
  year: 1996
  ident: 10.3349/ymj.2017.58.2.370_ref19
  publication-title: Intensive Care Med
  doi: 10.1007/BF01709751
– volume: 55
  start-page: 965
  year: 2012
  ident: 10.3349/ymj.2017.58.2.370_ref23
  publication-title: Hepatology
  doi: 10.1002/hep.25551
– volume: 11
  start-page: 299
  year: 2011
  ident: 10.3349/ymj.2017.58.2.370_ref37
  publication-title: BMC Infect Dis
  doi: 10.1186/1471-2334-11-299
– volume: 120
  start-page: c179
  year: 2012
  ident: 10.3349/ymj.2017.58.2.370_ref22
  publication-title: Nephron Clin Pract
  doi: 10.1159/000339789
– volume: 13
  start-page: 818
  year: 1985
  ident: 10.3349/ymj.2017.58.2.370_ref20
  publication-title: Crit Care Med
  doi: 10.1097/00003246-198510000-00009
– volume: 227
  start-page: 9
  year: 2009
  ident: 10.3349/ymj.2017.58.2.370_ref1
  publication-title: Immunol Rev
  doi: 10.1111/j.1600-065X.2008.00719.x
– volume: 2012
  start-page: 920517
  year: 2012
  ident: 10.3349/ymj.2017.58.2.370_ref14
  publication-title: Mediators Inflamm
  doi: 10.1155/2012/920517
– volume: 39
  start-page: 165
  year: 2013
  ident: 10.3349/ymj.2017.58.2.370_ref6
  publication-title: Intensive Care Med
  doi: 10.1007/s00134-012-2769-8
– volume: 8
  start-page: e53661
  year: 2013
  ident: 10.3349/ymj.2017.58.2.370_ref12
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0053661
– volume: 227
  start-page: 46
  year: 1997
  ident: 10.3349/ymj.2017.58.2.370_ref27
  publication-title: Scand J Clin Lab Invest Suppl
  doi: 10.1080/00365519709168308
– volume: 115
  start-page: 829
  year: 1999
  ident: 10.3349/ymj.2017.58.2.370_ref2
  publication-title: Chest
  doi: 10.1378/chest.115.3.829
– volume: 31
  start-page: 28
  year: 2009
  ident: 10.3349/ymj.2017.58.2.370_ref33
  publication-title: Shock
  doi: 10.1097/SHK.0b013e31817fd543
– volume: 37
  start-page: 242
  year: 2012
  ident: 10.3349/ymj.2017.58.2.370_ref36
  publication-title: Shock
  doi: 10.1097/SHK.0b013e3182454acf
– volume: 345
  start-page: 1368
  year: 2001
  ident: 10.3349/ymj.2017.58.2.370_ref17
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa010307
– volume: 31
  start-page: 545
  year: 2013
  ident: 10.3349/ymj.2017.58.2.370_ref39
  publication-title: Am J Emerg Med
  doi: 10.1016/j.ajem.2012.10.017
– volume: 38
  start-page: 241
  year: 2008
  ident: 10.3349/ymj.2017.58.2.370_ref24
  publication-title: Ann Clin Lab Sci
– volume: 51
  start-page: 907
  year: 2013
  ident: 10.3349/ymj.2017.58.2.370_ref34
  publication-title: Clin Chem Lab Med
  doi: 10.1515/cclm-2012-0459
– volume: 267
  start-page: 22190
  year: 1992
  ident: 10.3349/ymj.2017.58.2.370_ref3
  publication-title: J Biol Chem
  doi: 10.1016/S0021-9258(18)41653-5
– volume: 36
  start-page: 621
  year: 2010
  ident: 10.3349/ymj.2017.58.2.370_ref29
  publication-title: Intensive Care Med
  doi: 10.1007/s00134-010-1752-5
– reference: 24039869 - PLoS One. 2013 Sep 09;8(9):e73119
– reference: 23273657 - Heart Lung. 2013 Mar-Apr;42(2):139-45
– reference: 24321201 - Crit Care. 2013 Dec 09;17(6):R282
– reference: 11794169 - N Engl J Med. 2001 Nov 8;345(19):1368-77
– reference: 24476432 - N Engl J Med. 2014 Jan 30;370(5):421-32
– reference: 12955633 - Clin Infect Dis. 2003 Sep 15;37(6):745-51
– reference: 23853427 - Mediators Inflamm. 2013;2013:165974
– reference: 19120471 - Immunol Rev. 2009 Jan;227(1):9-18
– reference: 8844239 - Intensive Care Med. 1996 Jul;22(7):707-10
– reference: 10084499 - Chest. 1999 Mar;115(3):829-35
– reference: 23341967 - PLoS One. 2013;8(1):e53661
– reference: 20119647 - Intensive Care Med. 2010 Apr;36(4):621-9
– reference: 18650775 - Shock. 2009 Jan;31(1):28-32
– reference: 8634434 - Blood. 1996 Mar 1;87(5):1862-72
– reference: 19952319 - JAMA. 2009 Dec 2;302(21):2323-9
– reference: 1429570 - J Biol Chem. 1992 Nov 5;267(31):22190-7
– reference: 22040292 - BMC Infect Dis. 2011 Nov 01;11:299
– reference: 26632390 - Yonsei Med J. 2016 Jan;57(1):111-7
– reference: 18715852 - Ann Clin Lab Sci. 2008 Summer;38(3):241-6
– reference: 21840338 - J Infect. 2011 Dec;63(6):407-19
– reference: 19443038 - J Infect. 2009 Jun;58(6):425-32
– reference: 22213561 - Hepatology. 2012 Mar;55(3):965-7
– reference: 23361625 - Intensive Care Med. 2013 Feb;39(2):165-228
– reference: 15090974 - Crit Care Med. 2004 Mar;32(3):858-73
– reference: 21423699 - PLoS One. 2011 Mar 10;6(3):e17653
– reference: 9127468 - Scand J Clin Lab Invest Suppl. 1997;227:46-63
– reference: 23380094 - Am J Emerg Med. 2013 Mar;31(3):545-8
– reference: 12664219 - Intensive Care Med. 2003 Apr;29(4):530-8
– reference: 21880642 - Haematologica. 2011 Sep;96(9):1385-9
– reference: 3928249 - Crit Care Med. 1985 Oct;13(10):818-29
– reference: 22577258 - Mediators Inflamm. 2012;2012:920517
– reference: 22258230 - Shock. 2012 Mar;37(3):242-6
– reference: 22890468 - Nephron Clin Pract. 2012;120(4):c179-84
– reference: 18158437 - Crit Care Med. 2008 Jan;36(1):296-327
– reference: 11445697 - Crit Care Med. 2001 Jul;29(7):1404-7
– reference: 23152412 - Clin Chem Lab Med. 2013 Apr;51(4):907-13
– reference: 18596636 - Crit Care Med. 2008 Aug;36(8):2302-8
– reference: 23458767 - Expert Rev Anti Infect Ther. 2013 Mar;11(3):265-75
– reference: 21726354 - Respirology. 2011 Oct;16(7):1088-95
– reference: 3558716 - J Chronic Dis. 1987;40(5):373-83
SSID ssj0027102
Score 2.2146084
Snippet Pentraxin 3 (PTX3) has been suggested to be a prognostic marker of mortality in severe sepsis. Currently, there are limited data on biomarkers including PTX3...
Purpose: Pentraxin 3 (PTX3) has been suggested to be a prognostic marker of mortality in severe sepsis. Currently, there are limiteddata on biomarkers...
SourceID nrf
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 370
SubjectTerms Aged
APACHE
Biomarkers - blood
C-Reactive Protein - analysis
C-Reactive Protein - metabolism
Calcitonin - blood
Cause of Death
Female
Humans
Leukocyte Count
Male
Middle Aged
Neutrophils
Organ Dysfunction Scores
Original
Prognosis
Proportional Hazards Models
Prospective Studies
Reference Standards
ROC Curve
Sensitivity and Specificity
Sepsis - blood
Sepsis - mortality
Serum Amyloid P-Component - analysis
Time Factors
의학일반
Title Long Pentraxin 3 as a Predictive Marker of Mortality in Severe Septic Patients Who Received Successful Early Goal-Directed Therapy
URI https://www.ncbi.nlm.nih.gov/pubmed/28120568
https://www.proquest.com/docview/1861861815
https://pubmed.ncbi.nlm.nih.gov/PMC5290017
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002196523
Volume 58
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Yonsei Medical Journal, 2017, 58(2), , pp.370-379
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1976-2437
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0027102
  issn: 0513-5796
  databaseCode: KQ8
  dateStart: 20050101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1976-2437
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0027102
  issn: 0513-5796
  databaseCode: DOA
  dateStart: 20050101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1976-2437
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0027102
  issn: 0513-5796
  databaseCode: DIK
  dateStart: 19600101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 1976-2437
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0027102
  issn: 0513-5796
  databaseCode: GX1
  dateStart: 19600101
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
– providerCode: PRVERR
  databaseName: KoreaMed Open Access
  customDbUrl:
  eissn: 1976-2437
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0027102
  issn: 0513-5796
  databaseCode: 5-W
  dateStart: 19600101
  isFulltext: true
  titleUrlDefault: https://koreamed.org/journals
  providerName: Korean Association of Medical Journal Editors
– providerCode: PRVAQN
  databaseName: PubMed Central Free
  customDbUrl:
  eissn: 1976-2437
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0027102
  issn: 0513-5796
  databaseCode: RPM
  dateStart: 20050101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVFZP
  databaseName: Scholars Portal Journals: Open Access
  customDbUrl:
  eissn: 1976-2437
  dateEnd: 20250930
  omitProxy: true
  ssIdentifier: ssj0027102
  issn: 0513-5796
  databaseCode: M48
  dateStart: 20050201
  isFulltext: true
  titleUrlDefault: http://journals.scholarsportal.info
  providerName: Scholars Portal
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELe2ISFeEN9kQGUQT0guiT8S5wEhhBgDUVRpq7Y3K3HsrawkI22l7ZW_nDsnLRRVCCmSH2znw3c-_37x-Y6Ql6VXsatkyaROBQMrKZlWuWPW8hIqeJZZPDs8-poeTuTnU3W6Q1bprfoBnG-ldphPatLOhlc_rt_ChH-DjFPI_PX192_oo5UNlR7yociAwd-AhYmjko-k_s2_kuCCCGooGB7B7DY5t99iY5narVu_DYH-7Uj5x8p0cIfc7iElfdfpwF2y4-p75Oao3zS_T35-aeozOg6dr6Y1FbSY04KOW2yB1o7igR3X0sbTURgIQOYUGh450HMHBZgVS8ddBNY5PTlvKKBNBz0rerQMGRf9ckZDrGT6sSlmrDOkUH3cBS14QCYHH47fH7I-9QKzUogFkwBUHAcyprxweap5mUgrcuERn8R5oVUlKqBWXieOp977Ii-dtmWRxbpKeSIekr26qd1jQm2WhcBiaVlV0gNCkKVQEs1qHPusiiMSr0ba2D4uOabHmBngJygcA8IxKByjtOEGhBORV-sul11Qjn81fgHiMxd2ajCUNpZnjbloDRCGTwbIuBY6jcjzlXQNzC_cNClq1yznJtFpuBIVkUedtNfP5ICOAEDqiGQberBugA_crKmn5yGGt-I5AoT9_3m5J-QWflHn-faU7C3apXsGUGhRDsiuYieD8CNhEJT9FxI7CBM
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Long+Pentraxin+3+as+a+Predictive+Marker+of+Mortality+in+Severe+Septic+Patients+Who+Received+Successful+Early+Goal-Directed+Therapy&rft.jtitle=Yonsei+medical+journal&rft.au=%EA%B9%80%EC%84%A0%EB%B9%88&rft.au=%ED%95%9C%EC%83%81%ED%9B%88&rft.au=%EC%9D%B4%EA%B2%BD%ED%99%94&rft.au=%EC%9D%B4%EC%A7%80%EC%96%B8&rft.date=2017-03-01&rft.pub=%EC%97%B0%EC%84%B8%EB%8C%80%ED%95%99%EA%B5%90%EC%9D%98%EA%B3%BC%EB%8C%80%ED%95%99&rft.issn=0513-5796&rft.eissn=1976-2437&rft.spage=370&rft.epage=379&rft_id=info:doi/10.3349%2Fymj.2017.58.2.370&rft.externalDBID=n%2Fa&rft.externalDocID=oai_kci_go_kr_ARTI_1328386
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0513-5796&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0513-5796&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0513-5796&client=summon